177 related articles for article (PubMed ID: 11813174)
1. Prognostic impact of molecular genetic alterations in hepatoblastoma.
von Schweinitz D; Kraus JA; Albrecht S; Koch A; Fuchs J; Pietsch T
Med Pediatr Oncol; 2002 Feb; 38(2):104-8. PubMed ID: 11813174
[TBL] [Abstract][Full Text] [Related]
2. Characterization of genomic alterations in hepatoblastomas. A role for gains on chromosomes 8q and 20 as predictors of poor outcome.
Weber RG; Pietsch T; von Schweinitz D; Lichter P
Am J Pathol; 2000 Aug; 157(2):571-8. PubMed ID: 10934159
[TBL] [Abstract][Full Text] [Related]
3. [Genomic imbalance and chromosome disorders in hepatoblastoma].
Gao H; Zhang ZB; Ou YL; Zhang KR; Wang WL
Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):915-9. PubMed ID: 17533743
[TBL] [Abstract][Full Text] [Related]
4. Genetic alterations in hepatoblastoma and hepatocellular carcinoma: common and distinctive aspects.
Buendia MA
Med Pediatr Oncol; 2002 Nov; 39(5):530-5. PubMed ID: 12228912
[TBL] [Abstract][Full Text] [Related]
5. Allelic loss but absence of mutations in the polyspecific transporter gene BWR1A on 11p15.5 in hepatoblastoma.
Albrecht S; Hartmann W; Houshdaran F; Koch A; Gärtner B; Prawitt D; Zabel BU; Russo P; Von Schweinitz D; Pietsch T
Int J Cancer; 2004 Sep; 111(4):627-32. PubMed ID: 15239143
[TBL] [Abstract][Full Text] [Related]
6. Three non-overlapping regions of chromosome arm 11p allele loss identified in infantile tumors of adrenal and liver.
Byrne JA; Simms LA; Little MH; Algar EM; Smith PJ
Genes Chromosomes Cancer; 1993 Oct; 8(2):104-11. PubMed ID: 7504513
[TBL] [Abstract][Full Text] [Related]
7. Loss of heterozygosity on chromosome 11p15.5 and relapse in hepatoblastomas.
Chitragar S; Iyer VK; Agarwala S; Gupta SD; Sharma A; Wari MN
Eur J Pediatr Surg; 2011 Jan; 21(1):50-3. PubMed ID: 21053162
[TBL] [Abstract][Full Text] [Related]
8. Nuclear localization of beta-catenin is an important prognostic factor in hepatoblastoma.
Park WS; Oh RR; Park JY; Kim PJ; Shin MS; Lee JH; Kim HS; Lee SH; Kim SY; Park YG; An WG; Kim HS; Jang JJ; Yoo NJ; Lee JY
J Pathol; 2001 Apr; 193(4):483-90. PubMed ID: 11276007
[TBL] [Abstract][Full Text] [Related]
9. Mutations and elevated transcriptional activity of conductin (AXIN2) in hepatoblastomas.
Koch A; Weber N; Waha A; Hartmann W; Denkhaus D; Behrens J; Birchmeier W; von Schweinitz D; Pietsch T
J Pathol; 2004 Dec; 204(5):546-54. PubMed ID: 15538750
[TBL] [Abstract][Full Text] [Related]
10. High frequency of beta-catenin mutations in hepatoblastoma.
Udatsu Y; Kusafuka T; Kuroda S; Miao J; Okada A
Pediatr Surg Int; 2001 Sep; 17(7):508-12. PubMed ID: 11666046
[TBL] [Abstract][Full Text] [Related]
11. Somatic mutations of beta-catenin play a crucial role in the tumorigenesis of sporadic hepatoblastoma.
Jeng YM; Wu MZ; Mao TL; Chang MH; Hsu HC
Cancer Lett; 2000 Apr; 152(1):45-51. PubMed ID: 10754205
[TBL] [Abstract][Full Text] [Related]
12. Loss of heterozygosity on chromosome 1 in human hepatoblastoma.
Kraus JA; Albrecht S; Wiestler OD; von Schweinitz D; Pietsch T
Int J Cancer; 1996 Aug; 67(4):467-71. PubMed ID: 8759602
[TBL] [Abstract][Full Text] [Related]
13. [Differentiated treatment protocols for high- and standard-risk hepatoblastoma--an interim report of the German Liver Tumor Study HB99].
Häberle B; Bode U; von Schweinitz D
Klin Padiatr; 2003; 215(3):159-65. PubMed ID: 12778356
[TBL] [Abstract][Full Text] [Related]
14. Activation of beta-catenin in epithelial and mesenchymal hepatoblastomas.
Wei Y; Fabre M; Branchereau S; Gauthier F; Perilongo G; Buendia MA
Oncogene; 2000 Jan; 19(4):498-504. PubMed ID: 10698519
[TBL] [Abstract][Full Text] [Related]
15. p57(KIP2) is not mutated in hepatoblastoma but shows increased transcriptional activity in a comparative analysis of the three imprinted genes p57(KIP2), IGF2, and H19.
Hartmann W; Waha A; Koch A; Goodyer CG; Albrecht S; von Schweinitz D; Pietsch T
Am J Pathol; 2000 Oct; 157(4):1393-403. PubMed ID: 11021841
[TBL] [Abstract][Full Text] [Related]
16. Loss of heterozygosity in sporadic parathyroid tumours: involvement of chromosome 1 and the MEN1 gene locus in 11q13.
Dwight T; Twigg S; Delbridge L; Wong FK; Farnebo F; Richardson AL; Nelson A; Zedenius J; Philips J; Larsson C; Teh BT; Robinson B
Clin Endocrinol (Oxf); 2000 Jul; 53(1):85-92. PubMed ID: 10931084
[TBL] [Abstract][Full Text] [Related]
17. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene.
Koch A; Denkhaus D; Albrecht S; Leuschner I; von Schweinitz D; Pietsch T
Cancer Res; 1999 Jan; 59(2):269-73. PubMed ID: 9927029
[TBL] [Abstract][Full Text] [Related]
18. Efficiency and toxicity of ifosfamide, cisplatin and doxorubicin in the treatment of childhood hepatoblastoma. Study Committee of the Cooperative Paediatric Liver Tumour Study HB89 of the German Society for Paediatric Oncology and Haematology.
von Schweinitz D; Byrd DJ; Hecker H; Weinel P; Bode U; Bürger D; Erttmann R; Harms D; Mildenberger H
Eur J Cancer; 1997 Jul; 33(8):1243-9. PubMed ID: 9301450
[TBL] [Abstract][Full Text] [Related]
19. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
20. Genetic mosaicism at the insulin locus in liver associated with childhood hepatoblastoma.
Simms LA; Reeve AE; Smith PJ
Genes Chromosomes Cancer; 1995 May; 13(1):72-3. PubMed ID: 7541647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
